Evotec SE (EVO) Cash from Financing Activities (2009 - 2026)
Evotec SE (EVO) posted Cash from Financing Activities of -$22349.5 for Q1 2026, up 99.95% sequentially from -$43.8 million in Q4 2025, and down 159.97% YoY from $37267.2 in Q1 2025.
Evotec SE (EVO) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Evotec SE has reported Cash from Financing Activities for 9 years, with the latest figure at -$22349.5 in Q1 2026.
- Quarterly Cash from Financing Activities fell 159.97% year-over-year to -$22349.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.9 million (up 74.56% YoY) and the FY2025 annual result came in at -$43.8 million, up 74.61% from the prior year.
- Cash from Financing Activities rose to -$22349.5 in Q1 2026 per EVO's latest filing, from -$43.8 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $77.4 million in Q4 2023 and troughed at -$172.4 million in Q4 2024.
- A 5-year average of -$11.7 million and a median of -$7889.6 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities jumped 991.27% in 2023, then plunged 1780.81% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$59.3 million in 2022, then soared by 230.55% to $77.4 million in 2023, then plunged by 322.75% to -$172.4 million in 2024, then jumped by 74.58% to -$43.8 million in 2025, then surged by 99.95% to -$22349.5 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$22349.5, -$43.8 million, and -$14185.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Evotec SE | 687.23 Mn | 686.75 Mn | - | -22,349.53 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22,349.53 |
| Mar 31, 2026 | -22,349.53 |
| Dec 31, 2025 | -43.81 Mn |
| Dec 31, 2025 | -43.81 Mn |
| Sep 30, 2025 | -14,185.31 |
| Sep 30, 2025 | -14,185.31 |
| Jun 30, 2025 | -16,635.28 |
| Jun 30, 2025 | -16,635.28 |
| Mar 31, 2025 | 37,267.21 |
| Mar 31, 2025 | 37,267.21 |
| Dec 31, 2024 | -172.35 Mn |
| Dec 31, 2024 | -172.35 Mn |
| Sep 30, 2024 | -7,889.61 |
| Sep 30, 2024 | -7,889.61 |
| Jun 30, 2024 | -128,192.70 |
| Jun 30, 2024 | -128,192.70 |
| Mar 31, 2024 | -6,378.03 |
| Mar 31, 2024 | -6,378.03 |
| Dec 31, 2023 | 77.38 Mn |
| Dec 31, 2023 | 77.38 Mn |